Program Provides Molecular Characterization of Pediatric Cancers
The National Cancer Institute announced the launch of its Molecular Characterization Initiative for pediatric tumors. This program will provide biomarker testing free of charge to children, adolescents, and young adults with newly diagnosed CNS tumors who are receiving treatment at Children's Oncology Group–affiliated hospitals. Learn more about the Molecular Characterization Initiative.

Jazz Pharmaceuticals Completes FDA sBLA for Rylaze Dosing Schedule
Recently, Jazz Pharmaceuticals announced that the company completed the submission of a Supplemental Biologics License Application (sBLA) to the FDA seeking approval for a Monday/Wednesday/Friday IM dosing schedule for Rylaze. Learn more about its approval for use in patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who have developed hypersensitivity to E coli–derived asparaginase.

Long-Acting HIV Injectable Therapy Approved for Adolescents
The manufacturer, ViiV Healthcare, announced that the FDA approved Cabenuva for the treatment of HIV-1 in virologically suppressed adolescents who are aged 12 years or older and weigh at least 35 kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Read more.